Novacyt S.A. Liquidity Agreement and Total Voting Rights (5298Y)
January 03 2024 - 5:00AM
UK Regulatory
TIDMNCYT
RNS Number : 5298Y
Novacyt S.A.
03 January 2024
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Liquidity Agreement Monthly Update and Total Voting Rights
Paris, France, Eastleigh and Manchester, UK - 3 January 2024 -
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international
specialist in clinical diagnostics, announces its monthly update in
relation to ordinary shares traded under its ongoing liquidity
agreement with Invest Securities SA (the "Liquidity Agreement").
The Liquidity Agreement is governed by French law and is further
summarised below.
During the period from 1 December to 31 December 2023, Invest
Securities purchased 61,721 ordinary shares at a maximum price of
EUR0.79 and a minimum price of EUR0.69 and sold 57,524 ordinary
shares at a maximum price of EUR0.81 and a minimum price of EUR0.69
under the Liquidity Agreement. The total number of ordinary shares
in the Company, which are held in treasury as at close of business
on 31 December 2023, is 56,840.
Total Voting Rights
The total number of ordinary shares in the Company is
70,626,248. This figure may be used by shareholders as the
denominator for calculations by which they will determine if they
are required to notify their interest in, or a change to their
interest in, the Company pursuant to Article L. 223-7 of the French
Commercial Code and the Company's Articles. The Company is not
subject to the disclosure guidance and transparency rules made by
the Financial Conduct Authority under Part VI of FSMA.
Contacts
Novacyt SA +44 (0) 23 8074 8830
James Wakefield, Non-Executive
Chairman
James McCarthy, Acting Chief Executive
Officer
SP Angel Corporate Finance LLP (Nominated
Adviser and Broker) +44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Deutsche Numis (Joint Broker) +44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Michael
Palser
Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780
Stephanie Cuthbert / Anna Dunphy novacyt@walbrookpr.com
/ Phillip Marriage
About Novacyt Group
Novacyt is an international molecular diagnostics company
providing a broad portfolio of integrated technologies and
services, primarily focused on the delivery of genomic medicine.
The Company develops, manufactures, and commercialises a range of
molecular assays and instrumentation to deliver workflows and
services that enable seamless end-to-end solutions from sample to
result across multiple sectors including human health, animal
health and environmental.
Novacyt is headquartered in Vélizy in France with offices in the
UK (in Stokesley, Eastleigh and Manchester), Taipei (divestment
pending), Singapore, the US and Canada and has a commercial
presence in over 65 countries. The Company is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock
Exchange Euronext Growth ("ALNOV").
For more information, please refer to the website:
www.novacyt.com
Further information on the Liquidity Agreement
On 12 September 2016, the Company and Invest Securities entered
into the Liquidity Agreement pursuant to which Invest Securities
provides liquidity services in relation to the ordinary shares to
the Company. Invest Securities may purchase ordinary shares on
behalf of the Company under the agreement, subject to approval from
Shareholders as to the price at which ordinary shares can be
brought back and the aggregate amount that the Company may provide
to Invest Securities to purchase such ordinary shares.
Shareholder approval was granted at the Shareholders' meeting
held on 20 July 2022 for the purchase of ordinary shares by Invest
Securities under the agreement at a maximum purchase price per
ordinary shares of EUR12.00 for an aggregate maximum purchase price
of EUR200,000 and for 18 months from the date of the approval.
Under the agreement, Invest Securities must act completely
independently of the Company and the Company must not communicate
with the employees of Invest Securities who are responsible for
performing the agreement. Invest Securities is paid EUR10,000 per
annum for its services under the liquidity agreement. The agreement
has an initial term of two years, with a rolling extension of one
year thereafter. The agreement can be terminated by either party at
the end of each such period subject to two months' prior notice.
The Liquidity Agreement is governed by French law. Ordinary shares
purchased by Invest Securities are either cancelled or held as
treasury shares (which are non-voting and do not rank for
dividends).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRBXLFBZFLXBBQ
(END) Dow Jones Newswires
January 03, 2024 06:00 ET (11:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2024 to Jun 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From Jun 2023 to Jun 2024